JP2014531201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531201A5 JP2014531201A5 JP2014527743A JP2014527743A JP2014531201A5 JP 2014531201 A5 JP2014531201 A5 JP 2014531201A5 JP 2014527743 A JP2014527743 A JP 2014527743A JP 2014527743 A JP2014527743 A JP 2014527743A JP 2014531201 A5 JP2014531201 A5 JP 2014531201A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- derivative
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 74
- 230000004927 fusion Effects 0.000 claims description 68
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 70
- 102000036639 antigens Human genes 0.000 claims 70
- 108091007433 antigens Proteins 0.000 claims 70
- 231100000433 cytotoxic Toxicity 0.000 claims 19
- 230000001472 cytotoxic effect Effects 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 15
- 101150013553 CD40 gene Proteins 0.000 claims 13
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000003213 activating effect Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004443 dendritic cell Anatomy 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 231100000065 noncytotoxic Toxicity 0.000 claims 3
- 230000002020 noncytotoxic effect Effects 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 2
- 229940055742 indium-111 Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- -1 host cell Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 atom Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940097886 phosphorus 32 Drugs 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1115280.8A GB201115280D0 (en) | 2011-09-05 | 2011-09-05 | Antibodies, uses and methods |
| GB1115280.8 | 2011-09-05 | ||
| PCT/GB2012/052179 WO2013034904A1 (en) | 2011-09-05 | 2012-09-05 | Anti-cd40 antibodies, uses and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531201A JP2014531201A (ja) | 2014-11-27 |
| JP2014531201A5 true JP2014531201A5 (enExample) | 2015-11-05 |
| JP6324891B2 JP6324891B2 (ja) | 2018-05-16 |
Family
ID=44882205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527743A Active JP6324891B2 (ja) | 2011-09-05 | 2012-09-05 | 抗ｃｄ４０抗体、使用、および方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9676862B2 (enExample) |
| EP (2) | EP3323834B1 (enExample) |
| JP (1) | JP6324891B2 (enExample) |
| KR (1) | KR102029946B1 (enExample) |
| CN (1) | CN103930442B (enExample) |
| AU (1) | AU2012306071B2 (enExample) |
| CA (1) | CA2860406C (enExample) |
| CY (1) | CY1119925T1 (enExample) |
| DK (2) | DK2753646T3 (enExample) |
| ES (2) | ES2658157T3 (enExample) |
| GB (1) | GB201115280D0 (enExample) |
| HR (1) | HRP20180269T1 (enExample) |
| HU (1) | HUE036538T2 (enExample) |
| LT (1) | LT2753646T (enExample) |
| NO (1) | NO2753646T3 (enExample) |
| PL (1) | PL2753646T3 (enExample) |
| PT (1) | PT2753646T (enExample) |
| RS (1) | RS56868B1 (enExample) |
| RU (1) | RU2649055C2 (enExample) |
| SI (1) | SI2753646T1 (enExample) |
| SM (1) | SMT201800144T1 (enExample) |
| WO (1) | WO2013034904A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| EP2953634B1 (en) | 2013-02-07 | 2021-05-26 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| EA201790339A1 (ru) * | 2014-08-12 | 2017-06-30 | Аллигатор Байосайенс Аб | Комбинированные препараты с антителами к cd40 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| RS61531B1 (sr) | 2015-04-13 | 2021-04-29 | Five Prime Therapeutics Inc | Kombinovana terapija za kancer |
| FI3447075T3 (fi) | 2015-05-15 | 2023-11-07 | Massachusetts Gen Hospital | Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| KR20180053738A (ko) * | 2015-09-30 | 2018-05-23 | 얀센 바이오테크 인코포레이티드 | 인간 cd40과 특이적으로 결합하는 길항적 항체 및 사용 방법 |
| HUE057837T2 (hu) | 2015-11-03 | 2022-06-28 | Janssen Biotech Inc | PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik |
| WO2017197331A2 (en) | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2017205742A1 (en) * | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Anti-cd40 antibodies and their uses |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
| EP3534952A4 (en) | 2016-11-04 | 2020-06-10 | Memorial Sloan-Kettering Cancer Center | BI-SPECIFIC ACTIVATORS FOR ANTI-TUMOR THERAPY |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| US20200347143A1 (en) | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| BR112019025048A2 (pt) | 2017-06-01 | 2020-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos |
| MX2020002984A (es) | 2017-09-19 | 2020-07-22 | Mab Discovery Gmbh | Anticuerpos de cd40 agonistas. |
| CA3076872A1 (en) | 2017-11-03 | 2019-05-09 | Novartis Ag | Anti-cd40 antibodies for use in treatment of sjogren's syndrome |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US11976123B2 (en) | 2018-04-20 | 2024-05-07 | Lyvgen Biopharma Holdings Limited | Anti-CD40 antibodies and uses thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020065409A2 (en) * | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof |
| CN116063495A (zh) * | 2018-09-28 | 2023-05-05 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| MX2021006360A (es) | 2018-11-30 | 2021-08-11 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpo cd40 y uso de la misma. |
| MX2021005823A (es) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| SG11202112909SA (en) | 2019-05-28 | 2021-12-30 | Janssen Biotech Inc | Method of providing safe administration of an anti-cd40 antibody |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20210214454A1 (en) | 2020-01-10 | 2021-07-15 | Symphogen A/S | Anti-cd40 antibodies and compositions |
| GB202004677D0 (en) | 2020-03-31 | 2020-05-13 | Alligator Bioscience Ab | Methods and compositions |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022257908A1 (en) * | 2021-04-15 | 2023-11-30 | Icure Bnp Co., Ltd. | Cell-penetrating peptide, anti-cancer peptide, and pharmaceutical composition for preventing or treating cancer, comprising same |
| CN117295764A (zh) * | 2021-06-28 | 2023-12-26 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及医药用途 |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| IL312556A (en) * | 2021-11-05 | 2024-07-01 | Alligator Bioscience Ab | New peptides |
| CA3257929A1 (en) | 2022-05-31 | 2025-04-22 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use |
| KR20250029883A (ko) * | 2022-06-23 | 2025-03-05 | 엘리게이터 바이오사이언스 에이비 | 조합 요법 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| EP4643877A1 (en) * | 2022-12-28 | 2025-11-05 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Composition of cd40-binding molecule and pharmaceutical use thereof |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025093035A1 (en) * | 2023-11-03 | 2025-05-08 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| IN151589B (enExample) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5149796A (en) | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| ES2268799T3 (es) * | 1997-10-29 | 2007-03-16 | Genzyme Corporation | Terapia genica para la enfermedad de gaucher. |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| DE60110926T3 (de) | 2000-12-12 | 2012-06-14 | Alligator Bioscience Ab | Eine methode zur in vitro molekularen evolution der proteinfunktion |
| US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2003097834A2 (en) | 2002-05-17 | 2003-11-27 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| KR20070026522A (ko) * | 2004-04-27 | 2007-03-08 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법 |
| BRPI0610470A2 (pt) | 2005-05-26 | 2010-06-22 | Seattle Genetics Inc | anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado |
| EP2245065A1 (en) | 2008-01-23 | 2010-11-03 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
-
2011
- 2011-09-05 GB GBGB1115280.8A patent/GB201115280D0/en not_active Ceased
-
2012
- 2012-09-05 RS RS20180200A patent/RS56868B1/sr unknown
- 2012-09-05 JP JP2014527743A patent/JP6324891B2/ja active Active
- 2012-09-05 ES ES12761786.8T patent/ES2658157T3/es active Active
- 2012-09-05 SM SM20180144T patent/SMT201800144T1/it unknown
- 2012-09-05 DK DK12761786.8T patent/DK2753646T3/en active
- 2012-09-05 HU HUE12761786A patent/HUE036538T2/hu unknown
- 2012-09-05 HR HRP20180269TT patent/HRP20180269T1/hr unknown
- 2012-09-05 ES ES17195987T patent/ES2967316T3/es active Active
- 2012-09-05 SI SI201231140T patent/SI2753646T1/en unknown
- 2012-09-05 WO PCT/GB2012/052179 patent/WO2013034904A1/en not_active Ceased
- 2012-09-05 CN CN201280054090.1A patent/CN103930442B/zh active Active
- 2012-09-05 EP EP17195987.7A patent/EP3323834B1/en active Active
- 2012-09-05 LT LTEP12761786.8T patent/LT2753646T/lt unknown
- 2012-09-05 RU RU2014113304A patent/RU2649055C2/ru active
- 2012-09-05 US US14/342,141 patent/US9676862B2/en active Active
- 2012-09-05 PL PL12761786T patent/PL2753646T3/pl unknown
- 2012-09-05 CA CA2860406A patent/CA2860406C/en active Active
- 2012-09-05 EP EP12761786.8A patent/EP2753646B1/en active Active
- 2012-09-05 DK DK17195987.7T patent/DK3323834T3/da active
- 2012-09-05 PT PT127617868T patent/PT2753646T/pt unknown
- 2012-09-05 NO NO12761786A patent/NO2753646T3/no unknown
- 2012-09-05 AU AU2012306071A patent/AU2012306071B2/en active Active
- 2012-09-05 KR KR1020147008695A patent/KR102029946B1/ko active Active
-
2017
- 2017-05-08 US US15/588,919 patent/US10640567B2/en active Active
-
2018
- 2018-02-09 CY CY20181100161T patent/CY1119925T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531201A5 (enExample) | ||
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN110914306B (zh) | 检查点抑制物双特异性抗体 | |
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| JP2020501531A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2021518103A5 (enExample) | ||
| FI3618863T3 (fi) | Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi | |
| JP2017534253A5 (enExample) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP7350740B2 (ja) | Ｉｌｄｒ２アンタゴニストおよびその組み合わせ | |
| JP2017524343A5 (enExample) | ||
| IL272770B2 (en) | Agonistic cd40 antibodies | |
| BR112021006784A2 (pt) | Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| TW202114663A (zh) | EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途 | |
| HK40088417A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40088418A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40093821A (zh) | 多特异性抗体及其制备和使用方法 | |
| TH1901000369A (th) | แอนติ-gprc5d แอนติบอดี, โมเลกุลที่ยึดเหนี่ยวแอนติเจนแบบมีสองความจำเพาะซึ่งยึดเหนี่ยวgprc5d และ cd3 และการใช้สิ่งดังกล่าว | |
| HK40066348B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 |